Medifast, Inc. financials

  1. Home
  2. Financials
  3. MED
MED CIK 0000910329

Source: EDGAR filings · Built 2026-06-02T03:32:12Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 1.25M 17.02M 141.17M 177.89M 60.34M 139.31M
EBITDA 29.00K 15.59M 139.51M 195.79M 223.05M 138.47M
Working Capital 158.72M 150.24M 131.73M 81.89M 137.03M 122.96M
Net Debt -78.61M -74.80M -72.43M -61.64M -71.64M -152.56M
Gross Margin 71.33% 73.80% 72.37% 71.34% 73.89% 74.65%
Operating Margin -3.68% 0.48% 11.79% 11.56% 14.17% 14.35%
Net Margin -4.84% 0.35% 9.27% 8.98% 10.75% 11.00%
Return on Equity (ROE) -9.39% 1.00% 49.34% 92.60% 81.01% 65.41%
Return on Assets (ROA) -7.53% 0.74% 32.08% 45.40% 41.18% 37.26%
Current Ratio 4.69× 3.34× 2.43× 1.58× 1.81× 2.10×
Debt-to-Equity 0.05× 0.08× 0.11× 0.17× 0.16× 0.07×
Effective Tax Rate -231.12% 44.78% 22.81% 22.00% 24.11% 23.39%
Cash Conversion Ratio -0.37× 11.71× 1.49× 1.36× 0.58× 1.41×
Accruals Ratio -0.10× -0.08× -0.16× -0.16× 0.17× -0.15×
SBC % of Revenue 1.98% 1.22% 0.76% 0.69% 0.65% 0.73%
CapEx Coverage 1.22× 3.28× 22.78× 11.66× 2.76× 24.66×
Free Cash Flow Per Share $0.11 $1.55 $12.93 $15.78 $5.11 $11.76

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) — 92.74× 7.39× 9.06× 15.08× 22.62×
P/FCF 93.93× 11.35× 5.20× 7.31× 41.00× 16.70×
FCF Yield 1.06% 8.81% 19.23% 13.68% 2.44% 5.99%
EV / EBITDA 1337.06× 7.57× 4.73× 6.09× 10.56× 15.59×
P/S 0.30× 0.32× 0.68× 0.78× 1.59× 2.47×
P/B 0.59× 0.92× 3.64× 8.09× 11.99× 14.70×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 385.79M 602.46M 1.07B 1.60B 1.53B —
Revenues — — — — — 934.84M
Cost of Revenue 110.60M 157.84M 296.20M 458.16M 398.49M 237.03M
Gross Profit 275.19M 444.62M 775.85M 1.14B 1.13B 697.82M
Research and Development Expense 4.30M 4.60M 4.60M 4.50M 4.40M 2.80M
Selling, General and Administrative Expense 289.40M 441.75M 649.45M 955.61M 911.36M 563.66M
Operating Income (Loss) -14.21M 2.88M 126.40M 184.81M 216.24M 134.16M
Income Tax Expense (Benefit) 13.03M 1.70M 29.38M 40.49M 52.10M 31.41M
Net Income (Loss) Attributable to Parent -18.67M 2.09M 99.42M 143.57M 164.03M 102.86M
Earnings Per Share, Basic $-1.70 $0.19 $9.13 $12.82 $14.01 $8.74
Weighted Average Number of Shares Outstanding, Basic 10.98M 10.93M 10.88M 11.20M 11.71M 11.77M
Earnings Per Share, Diluted $-1.70 $0.19 $9.10 $12.73 $13.89 $8.68
Weighted Average Number of Shares Outstanding, Diluted 10.98M 10.96M 10.92M 11.28M 11.81M 11.85M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 89.30M 90.93M 94.44M 87.69M 104.18M 163.72M
Assets, Current 201.68M 214.40M 224.03M 222.78M 306.87M 234.31M
Assets 247.97M 284.21M 309.91M 316.21M 398.33M 276.08M
Liabilities, Current 42.96M 64.16M 92.30M 140.89M 169.83M 111.35M
Liabilities 49.05M 74.10M 108.43M 161.17M 195.85M 118.84M
Stockholders' Equity Attributable to Parent 198.92M 210.11M 201.48M 155.04M 202.47M 157.25M
Common Stock, Shares, Outstanding 10.99M 10.94M 10.90M 10.87M 11.59M 11.77M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 6.86M 24.48M 147.66M 194.57M 94.55M 145.20M
Payments to Acquire Property, Plant, and Equipment 5.61M 7.45M 6.48M 16.68M 34.21M 5.89M
Net Cash Provided by (Used in) Investing Activities -7.93M -26.52M -61.05M -11.41M -29.06M -1.28M
Payments for Repurchase of Common Stock 0 0 3.60M 126.44M 56.00M 5.00M
Payments of Dividends 195.00K 715.00K 73.02M 71.62M 63.86M 53.19M
Net Cash Provided by (Used in) Financing Activities -564.00K -1.51M -79.79M -199.58M -125.13M -57.14M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MED CIK 0000910329), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

BANC

BANC OF CALIFORNIA, INC.

HURN

HURON CONSULTING GROUP INC.

ROIV

ROIVANT SCIENCES LTD.